This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
by Zacks Equity Research
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
by Zacks Equity Research
Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
by Zacks Equity Research
Corvus' (CRVS) lead candidate, soquelitinib, gets orphan drug designation in the United States. The company???s shares rise 10.75% on the news.
What Makes Corvus (CRVS) a New Buy Stock
by Zacks Equity Research
Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?
by Zacks Equity Research
Here is how Corvus Pharmaceuticals (CRVS) and Cue Biopharma, Inc. (CUE) have performed compared to their sector so far this year.
Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Corvus Pharmaceuticals (CRVS) and Journey Medical Corporation (DERM) have performed compared to their sector so far this year.
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and Corvus Pharmaceuticals (CRVS) have performed compared to their sector so far this year.
Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why
by Zacks Equity Research
Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.
Corvus (CRVS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The Zacks Analyst Blog Highlights: Condor Hospitality Trust, Corvus Pharmaceuticals, Covenant Logistics and Herc Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Condor Hospitality Trust, Corvus Pharmaceuticals, Covenant Logistics and Herc Holdings
4 Buy-Ranked Stocks that Soared Over 20% in the Past Week
by Sejuti Banerjea
The market remains on its toes as investors digest the ton of information hitting us about now.
Evelo (EVLO) Posts Positive Data from Phase II Psoriasis Study
by Zacks Equity Research
Evelo Biosciences (EVLO) reports encouraging data from a phase II study evaluating EDP1815 for the treatment of mild and moderate psoriasis. Shares up in pre-market trading.
Ultragenyx (RARE) Reports FDA Removal of Clinical Hold on Study
by Zacks Equity Research
Ultragenyx (RARE) and GeneTx Biotherapeutics to start dosing in the phase I/II study on GTX-102 for treating pediatric patients with Angelman syndrome after the FDA removes its clinical hold on the same.
Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan
by Zacks Equity Research
Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.
Implied Volatility Surging for Corvus Pharmaceuticals (CRVS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Corvus Pharmaceuticals (CRVS) stock based on the movements in the options market lately.
BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma
by Zacks Equity Research
The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study
by Zacks Equity Research
RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal.
Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran
by Zacks Equity Research
Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
BeiGene's (BGNE) BLA for Tislelizumab in ESCC Accepted by FDA
by Zacks Equity Research
The FDA accepts for review BeiGene's (BGNE) BLA for tislelizumab to treat patients with locally advanced/metastatic esophageal squamous cell carcinoma after prior systemic therapy.
Apellis (APLS) Down on Mixed Data From Studies on GA Candidate
by Zacks Equity Research
Apellis (APLS) posts mixed top-line data from the phase III DERBY and OAKS studies testing pegcetacoplan in adults with geographic atrophy secondary to age-related macular degeneration. Stock falls.
Global Blood's (GBT) NDA & sNDA for Oxbryta Get Priority Review
by Zacks Equity Research
The FDA grants priority review to Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to 11 years, as well as to its NDA for a pediatric weight-based formulation of the drug.
Precision (DTIL) Inks Deal With Tiziana for Cancer Candidate
by Zacks Equity Research
Precision (DTIL) signs an exclusive license agreement with Tiziana to explore the latter's fully human anti-CD3 mAb, foralumab, for treating various cancer indications. Stock up.
BeiGene (BGNE) Gets FDA Nod for Brukinsa Label Expansion
by Zacks Equity Research
The FDA approves BeiGene's (BGNE) Brukinsa for the treatment of adult patients with Waldenstrom's macroglobulinemia. This marks the second approval for the drug in the United States.